Written by Admin | Apr 1, 2019
The use of real world data to assess the safety and effectiveness of drugs and medical treatments is among the most controversial topics in medicine. As chief executive of Aetion, a New York City startup that sells software to analyze those data, Carolyn Magill is in the middle of the fray — one whose outcome will have a huge impact on how medicines are studied and priced in the future.
Read More